Quoin Pharmaceuticals Stock (NASDAQ:QNRX)


ForecastOwnershipFinancialsChart

Previous Close

$6.58

52W Range

$5.27 - $41.80

50D Avg

$7.73

200D Avg

$9.95

Market Cap

$3.80M

Avg Vol (3M)

$100.69K

Beta

1.82

Div Yield

-

QNRX Company Profile


Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

3

IPO Date

Aug 01, 2016

Website

QNRX Performance


QNRX Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-9.53M$-9.38M
Net Income$-15.80B$-8.96M$-8.69M
EBITDA-$-9.43M$-9.27M
Basic EPS$-14.80K$-66.85$-337.47
Diluted EPS$-14.80K$-66.85$-337.47

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 23Mar 14, 24 | 8:30 AM
Q3 23Nov 09, 23 | 8:30 AM
Q2 23Aug 07, 23 | 8:30 AM

Peer Comparison


TickerCompany
RADXRadiopharm Theranostics Limited
VIVSVivoSim Labs, Inc.
XTLBXTL Biopharmaceuticals Ltd.
PLRZPolyrizon Ltd.
PMCBPharmaCyte Biotech, Inc.
VYNEVYNE Therapeutics Inc.
KTTAPasithea Therapeutics Corp.
TCRTAlaunos Therapeutics, Inc.
CYCNCyclerion Therapeutics, Inc.